Towards a molecular classification of pulmonary arterial hypertension

European Respiratory Journal

Volumn 48, Issue 4, 2016, Pages 987-989

  Gräf, Stefan ^a   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CAVEOLIN 1; ENDOGLIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNK3; SMAD PROTEIN; SMAD9 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX4; UNCLASSIFIED DRUG;

BMPR2 GENE; CONSANGUINITY; EIF2AK4 GENE; FAMILY HISTORY; GENE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; PRIORITY JOURNAL; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW;

FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION, PULMONARY;

EID: 84990064435     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01550-2016     Document Type: Review

References (30)

1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975.
2. Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 2015; 148: 1043-1054.
3. Evans JD, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4: 129-137.
4. Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res 2014; 115: 189-202.
5. Morrell NW, Bloch DB, ten Dijke P, et al. Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev Cardiol 2016; 13: 106-120.
6. Long L, Ormiston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015; 21: 777-785.
7. Spiekerkoetter E, Tian X, Cai J, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013; 123: 3600-3613.
8. Spiekerkoetter E, Sung YK, Sudheendra D, et al. Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 254-257.
9. Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Hum Mutat 2015; 36: 1113-1127.
10. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-334.
11. Chaouat A, Coulet F, Favre C, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004; 59: 446-448.
12. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5: 336-343.
13. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369: 351-361.
14. Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT, et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet 2013; 50: 500-506.
15. Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46: 65-69.
16. Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 2014; 145: 231-236.
17. Tenorio J, Navas P, Barrios E, et al. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin Genet 2015; 88: 579-583.
18. Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2016; 47: 1518-1534.
19. Levy M, Eyries M, Szezepanski I, et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J 2016; 48: 1118-1126.
20. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
21. Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J 2015; 46: 1711-1720.
22. Bongers EM, Duijf PH, van Beersum SE, et al. Mutations in the human TBX4 gene cause small patella syndrome. Am J Hum Genet 2004; 74: 1239-1248.
23. Rodriguez-Esteban C, Tsukui T, Yonei S, et al. The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity. Nature 1999; 398: 814-818.
24. Girerd B, Montani D, Jaïs X, et al. Genetic counselling in a national referral centre for pulmonary hypertension. Eur Respir J 2016; 47: 541-552.
25. Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014; 46: 310-315.
26. Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med 2016; 8: 322ra9.
27. Walsh R, Thomson K, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7, 855 cardiomyopathy cases and 60, 706 reference samples. Genet Med 2016; in press [DOI: http://dx.doi.org/10.1101/041111].
28. Walter K, Min JL, Huang J, et al. The UK10K project identifies rare variants in health and disease. Nature 2015; 526: 82-90.
29. Exome Aggregation Consortium, Lek M, Karczewski K, et al. Analysis of protein-coding genetic variation in 60, 706 humans. Nature 2016; in press [DOI: 10.1101/030338].
30. Telenti A, Pierce LT, Biggs WH, et al. Deep sequencing of 10, 000 human genomes. bioRxiv 061663; http://dx.doi. org/10.1101/061663